BRASILIA (Reuters) – Brazilian health regulator Anvisa on Wednesday gave the go-ahead for the Butanvac vaccine developed by Sao Paulo’s Butantan Institute biomedical center to be used on volunteers as part of clinical trials.
In a statement, Anvisa said the vaccine will be applied in two doses, 28 days apart. Phase 1 of Butanvac’s clinical trial will involve 400 volunteers, and the first two phases are expected to have 6,000 volunteers in total.
(Reporting by Jamie McGeever; Editing by Leslie Adler)
